Press Releases

Press Releases

ESSA Pharma Inc. announced today that the U.S. Food and Drug Administration ("FDA") has approved its Investigational New Drug ("IND") application to initiate a Phase 1/2 clinical study of its novel agent, EPI-506, for the treatment of metastatic castration-resistant prostate cancer ("CRPC") in patients who have failed current therapies.  Enrolment…

Press Releases

OncoRx Pharmaceuticals, Inc. is announcing its launch as an early-stage pharmaceutical company focused on the development of drug therapies that control the progression of therapy-resistant malignant tumors. OncoRx has exclusively licensed the patent rights for drugs that target and control the proliferation and invasiveness of self-renewing cancer stem cells, aggressive…

Press Releases

Depomed, Inc. today announced favorable decisions by the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office that confirmed the patentability of all 23 claims of two Depomed patents (U.S. Patent Nos. 6,340,475 and 6,635,280) subject to inter partes review proceedings (IPRs) initiated by Endo…

Press Releases

Armetheon, Inc., a specialty pharmaceutical company developing novel small molecule drugs for cardiovascular diseases, today announced that Armetheon and China Cardiovascular Focus Limited, a subsidiary of Lee's Pharmaceutical Holdings Limited (Lee's Pharma), a public biopharmaceutical company listed on the main board of Hong Kong Stock Exchange (stock code: 950) with…

Press Releases

Impax Laboratories, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved its generic version of Testred Capsules 10 mg. "This represents the second Abbreviated New Drug Application approval from the Hayward, CA facility following resolution of the warning letter in early September 2015," said Fred Wilkinson,…

Press Releases

Selexis SA, a serial innovation company with proven technologies for characterized mammalian Research Cell Banks (RCBs) used for drug discovery to commercial manufacturing, announced today the signing of a Service Agreement with Swedish Orphan Biovitrum AB (Sobi), a leading biopharmaceutical company focused developing therapies and services for people living with…

Press Releases

RegeneRx Biopharmaceuticals, Inc., a clinical-stage drug development company focused on tissue protection, repair and regeneration, announced today that the first patient has been enrolled in a Phase 3 clinical trial with RGN-259 (designated GBT-201 in Korea), its sterile, preservative-free eye drop formulation developed for patients with dry eye syndrome, neurotrophic…

Press Releases

K-PAX Pharmaceuticals, Inc., a pioneer in immune function and energy metabolism medicines, today announced that the United States Patent and Trademark Office (US PTO) has issued an U.S. Patent for a repurposed version of methylphenidate (No.13/530,673) to the company. The patent is directed to compositions and methods for the treatment…

Press Releases

Boehringer Ingelheim and BioMed X announced today that they have successfully applied a crowdsourcing approach to establish a research team of outstanding scientists from around the world with bright ideas, who will endeavor to identify new approaches for the treatment of patients with chronic obstructive pulmonary disease (COPD). COPD is…

Press Releases

BerGenBio AS, an oncology biopharmaceutical company, has announced new preclinical data on lead compound, BGB324, in combination with immune checkpoint inhibitors, has been presented as a poster at CRI-CIMT-EATI-AACR - The Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival, in New York. This preclinical data highlights that BGB324, a…